Digiliti Money Group (OTCMKTS: DGLT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Digiliti Money Group and Iovance Biotherapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Digiliti Money Group 0 0 1 0 3.00
Iovance Biotherapeutics 0 0 10 0 3.00

Digiliti Money Group presently has a consensus target price of $6.00, suggesting a potential upside of 3,900.00%. Iovance Biotherapeutics has a consensus target price of $15.31, suggesting a potential upside of 87.88%. Given Digiliti Money Group’s higher probable upside, research analysts clearly believe Digiliti Money Group is more favorable than Iovance Biotherapeutics.

Institutional & Insider Ownership

11.3% of Digiliti Money Group shares are held by institutional investors. Comparatively, 75.9% of Iovance Biotherapeutics shares are held by institutional investors. 50.9% of Digiliti Money Group shares are held by company insiders. Comparatively, 13.2% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Digiliti Money Group has a beta of -0.66, indicating that its stock price is 166% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 4.59, indicating that its stock price is 359% more volatile than the S&P 500.

Profitability

This table compares Digiliti Money Group and Iovance Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Digiliti Money Group -147.73% N/A -199.21%
Iovance Biotherapeutics N/A -53.59% -51.25%

Earnings and Valuation

This table compares Digiliti Money Group and Iovance Biotherapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Digiliti Money Group $7.97 million 0.19 -$15.16 million N/A N/A
Iovance Biotherapeutics N/A N/A -$52.89 million ($1.30) -6.27

Digiliti Money Group has higher revenue and earnings than Iovance Biotherapeutics.

About Digiliti Money Group

Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Receive News & Ratings for Digiliti Money Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digiliti Money Group and related companies with MarketBeat.com's FREE daily email newsletter.